Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCND2 | P30279 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742044 | 1.00 | MEN1 (0.47) | MEN1KMT2AMAPK10GFERBRD4 | |
| SCHEMBL24374901 | 0.82 | BTK (0.40) | BRD4BTKTYK2POLBGAA | |
| SCHEMBL255387 | 0.82 | MKNK2 (0.47) | BTK | |
| SCHEMBL14917675 | 0.81 | MKNK1 (0.42) | MEN1KMT2ABTKTYK2NPC1 | |
| SCHEMBL24374650 | 0.80 | MEN1 (0.44) | MEN1KMT2AMAPK10GFERBRD4 | |
| SCHEMBL12602969 | 0.80 | BTK (0.46) | BTKTYK2NPC1RAB9ALYN | |
| SCHEMBL1725758 | 0.78 | BTK (0.39) | BTKTYK2LYN | |
| SCHEMBL1323108 | 0.78 | XIAP (0.36) | MEN1KMT2ABRD4BTKRAB9A | |
| SCHEMBL10255868 | 0.78 | MAPK14 (0.47) | MAPK10BTKTYK2LYNSRC | |
| SCHEMBL14933856 | 0.78 | BTK (0.35) | BTKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263552-A1 | BTK DEGRADER | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022133184-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| CN-110818724-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107253963-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110818724-A | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2566869-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | Gilead Connecticut, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | MEN1 4351/4885KMT2A 2703/4885MAPK10 504/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | MEN1 2841/4885KMT2A 2237/4885MAPK10 596/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | MEN1 2334/4885KMT2A 3222/4885MAPK10 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.